Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Rhea-AI Summary

Ceribell (Nasdaq: CBLL) will release fourth quarter and full year 2025 financial results after market close on February 24, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live and archived webcast available in Investor Relations.

The Ceribell System is described as a portable, AI-powered point-of-care EEG platform and is FDA-cleared for detecting seizure and delirium in acute-care settings.

Key Figures

Earnings release date: February 24, 2026 Conference call time PT: 1:30 p.m. PT Conference call time ET: 4:30 p.m. ET +1 more

4 metrics

Earnings release date February 24, 2026 Q4 and full-year 2025 results release after market close

Conference call time PT 1:30 p.m. PT Start time for earnings conference call on February 24, 2026

Conference call time ET 4:30 p.m. ET Start time for earnings conference call on February 24, 2026

Conference call access code 9394689 Access code for investors dialing into the earnings call

Market Reality Check

Price: $20.79 Vol: Volume 310,937 is slightl...

normal vol

$20.79 Last Close

Volume Volume 310,937 is slightly below the 20-day average of 346,980 (relative volume 0.9x). normal

Technical Shares trade above the 200-day MA of $16.07, with price at $20.90 pre-announcement.

Peers on Argus

CBLL gained 3.72% while key medical device peers were mostly down (e.g., SMLR -4...

CBLL gained 3.72% while key medical device peers were mostly down (e.g., SMLR -4.75%, TMCI -2.64%, BFLY -1.19%), indicating a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Breakthrough designation	Positive	-2.3%	FDA Breakthrough Device Designation for LVO stroke detection and monitoring.
Dec 30	Conference participation	Neutral	+1.0%	Planned presentation at the 44th J.P. Morgan Healthcare Conference.
Dec 09	Regulatory clearance	Positive	+5.0%	FDA 510(k) clearance for first-of-its-kind delirium monitoring solution.
Nov 24	Regulatory clearance	Positive	+4.9%	FDA 510(k) clearance for Clarity algorithm covering seizures across all ages.
Nov 19	Conference participation	Neutral	-0.1%	Planned presentation at Piper Sandler 37th Annual Healthcare Conference.

Pattern Detected

Regulatory clearances and breakthrough designations have generally seen positive price reactions, with one notable divergence on the LVO Breakthrough Device news.

Recent Company History

Over the last few months, Ceribell has focused on regulatory and visibility milestones. In Nov–Dec 2025, it secured multiple FDA 510(k) clearances, including delirium and neonatal seizure monitoring, with favorable one-day moves near +5%. Conference participation in late 2025 and early 2026 produced modest stock reactions. The Jan 5, 2026 FDA Breakthrough Device Designation for LVO stroke detection saw a slight decline, showing occasional divergence between strong news and immediate price action. Today’s earnings-date announcement fits this pattern of steady news flow.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-04

$300,000,000 registered capacity

Ceribell has an effective S-3 shelf filed on Nov 4, 2025, allowing up to $300,000,000 of securities to be offered in one or more future transactions, with terms defined in subsequent prospectus supplements. No takedowns have been recorded in the provided data (usage_count 0).

Market Pulse Summary

This announcement sets the timetable for Ceribell’s Q4 and full-year 2025 results on February 24, 20...

Analysis

This announcement sets the timetable for Ceribell’s Q4 and full-year 2025 results on February 24, 2026, adding an upcoming fundamental checkpoint to a story recently driven by FDA clearances and a Breakthrough Device Designation. With shares trading above the $16.07 200-day MA and an unused $300,000,000 universal shelf in place, investors may focus on how management’s commentary, growth metrics, and any updates on commercial execution compare with the regulatory progress highlighted in late 2025.

Key Terms

electroencephalography, eeg, artificial intelligence, fda-cleared

4 terms

electroencephalography medical

"a novel, point-of-care electroencephalography (“EEG”) platform specifically designed"

Electroencephalography is a medical test that uses small sensors on the scalp to record the brain’s electrical activity over time, like an EKG for the brain. Investors care because EEG data can be used in drug and device development, patient diagnosis, and monitoring treatment effects; strong EEG results can influence clinical success, regulatory approvals, and market adoption, affecting a company’s value and risk profile.

eeg medical

"electroencephalography (“EEG”) platform specifically designed to address the unmet needs"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

artificial intelligence technical

"with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

fda-cleared regulatory

"The Ceribell System is FDA-cleared for use in detecting seizure and delirium"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. Not financial advice.

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Brian Price
Press@ceribell.com  

FAQ

When will Ceribell (CBLL) report Q4 and full year 2025 financial results?

Ceribell will report fourth quarter and full year 2025 results after market close on February 24, 2026. According to Ceribell, the company will release results after the close of trading and host a conference call that same day at 1:30 p.m. PT / 4:30 p.m. ET.

How can investors join the Ceribell (CBLL) earnings conference call on February 24, 2026?

Investors can join by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with access code 9394689. According to Ceribell, a live and archived webcast will also be available in the Investor Relations section of the company website.

Where will the Ceribell (CBLL) webcast of the February 24, 2026 call be available?

The live and archived webcast will be posted in Ceribell's Investor Relations website. According to Ceribell, listeners can access the webcast at https://investors.ceribell.com for live listening and later replay.

What is the Ceribell System and what clinical uses is it cleared for?

The Ceribell System is a portable, AI-powered point-of-care EEG platform for acute-care settings. According to Ceribell, it is FDA-cleared for detecting seizure and delirium in intensive care units and emergency rooms across the U.S.

Who should investors contact for questions about Ceribell (CBLL) investor relations?

Investors can contact Brian Johnston or Laine Morgan at Gilmartin Group via Investors@ceribell.com. According to Ceribell, investor inquiries are directed to that email and the Investor Relations team for assistance and call access details.